Suppr超能文献

用于血清 CA125 定量的可编程生物纳米芯片系统:迈向即时护理点的卵巢癌诊断。

Programmable bio-nano-chip systems for serum CA125 quantification: toward ovarian cancer diagnostics at the point-of-care.

机构信息

Departments of Bioengineering and Chemistry, Rice University, Houston, TX 77005, USA.

出版信息

Cancer Prev Res (Phila). 2012 May;5(5):706-16. doi: 10.1158/1940-6207.CAPR-11-0508. Epub 2012 Apr 9.

Abstract

Point-of-care (POC) implementation of early detection and screening methodologies for ovarian cancer may enable improved survival rates through early intervention. Current laboratory-confined immunoanalyzers have long turnaround times and are often incompatible with multiplexing and POC implementation. Rapid, sensitive, and multiplexable POC diagnostic platforms compatible with promising early detection approaches for ovarian cancer are needed. To this end, we report the adaptation of the programmable bio-nano-chip (p-BNC), an integrated, microfluidic, and modular (programmable) platform for CA125 serum quantitation, a biomarker prominently implicated in multimodal and multimarker screening approaches. In the p-BNCs, CA125 from diseased sera (Bio) is sequestered and assessed with a fluorescence-based sandwich immunoassay, completed in the nano-nets (Nano) of sensitized agarose microbeads localized in individually addressable wells (Chip), housed in a microfluidic module, capable of integrating multiple sample, reagent and biowaste processing, and handling steps. Antibody pairs that bind to distinct epitopes on CA125 were screened. To permit efficient biomarker sequestration in a three-dimensional microfluidic environment, the p-BNC operating variables (incubation times, flow rates, and reagent concentrations) were tuned to deliver optimal analytical performance under 45 minutes. With short analysis times, competitive analytical performance (inter- and intra-assay precision of 1.2% and 1.9% and limit of detection of 1.0 U/mL) was achieved on this minisensor ensemble. Furthermore, validation with sera of patients with ovarian cancer (n = 20) showed excellent correlation (R(2) = 0.97) with gold-standard ELISA. Building on the integration capabilities of novel microfluidic systems programmed for ovarian cancer, the rapid, precise, and sensitive miniaturized p-BNC system shows strong promise for ovarian cancer diagnostics.

摘要

即时检测(POC)实施卵巢癌早期检测和筛查方法,通过早期干预可能提高生存率。目前的实验室局限的免疫分析仪具有较长的周转时间,并且通常与多重分析和 POC 实施不兼容。需要快速、敏感和可多重分析的 POC 诊断平台,与卵巢癌的有前途的早期检测方法兼容。为此,我们报告了可编程生物纳米芯片(p-BNC)的适应性,该芯片是用于 CA125 血清定量的集成、微流体和模块化(可编程)平台,CA125 是一种明显与多模态和多标志物筛查方法相关的生物标志物。在 p-BNC 中,从患病血清(Bio)中分离并评估 CA125,采用基于荧光的夹心免疫测定法,在定位在单独寻址孔(Chip)中的敏化琼脂糖微珠的纳米网(Nano)中完成,位于微流体模块中,能够集成多个样本、试剂和生物废物处理和处理步骤。筛选了与 CA125 上不同表位结合的抗体对。为了在三维微流体环境中有效地进行生物标志物的分离,p-BNC 的操作变量(孵育时间、流速和试剂浓度)进行了调整,以在 45 分钟内实现最佳分析性能。在这个迷你传感器组合上,具有较短的分析时间,可实现竞争性分析性能(批内和批间精度分别为 1.2%和 1.9%,检测限为 1.0 U/mL)。此外,用 20 例卵巢癌患者的血清进行验证,与金标准 ELISA 显示出极好的相关性(R² = 0.97)。基于为卵巢癌编程的新型微流体系统的集成能力,快速、精确和敏感的微型 p-BNC 系统显示出在卵巢癌诊断方面的巨大应用潜力。

相似文献

8
Lab-on-a-Disc for Point-of-Care Infection Diagnostics.基于光盘的即时感染诊断实验室。
Acc Chem Res. 2021 Oct 5;54(19):3643-3655. doi: 10.1021/acs.accounts.1c00367. Epub 2021 Sep 13.
9
Validation of a Novel Biomarker Panel for the Detection of Ovarian Cancer.用于检测卵巢癌的新型生物标志物组合的验证
Cancer Epidemiol Biomarkers Prev. 2016 Sep;25(9):1333-40. doi: 10.1158/1055-9965.EPI-15-1299. Epub 2016 Jul 22.

引用本文的文献

5
Different Approaches to Develop Nanosensors for Diagnosis of Diseases.开发用于疾病诊断的纳米传感器的不同方法。
Adv Sci (Weinh). 2020 Oct 28;7(24):2001476. doi: 10.1002/advs.202001476. eCollection 2020 Dec.

本文引用的文献

3
Cancer statistics, 2010.癌症统计数据,2010 年。
CA Cancer J Clin. 2010 Sep-Oct;60(5):277-300. doi: 10.3322/caac.20073. Epub 2010 Jul 7.
7
Microfluidic, bead-based assay: Theory and experiments.微流控,基于珠粒的检测法:理论与实验。
J Chromatogr B Analyt Technol Biomed Life Sci. 2010 Jan 15;878(2):228-36. doi: 10.1016/j.jchromb.2009.08.050. Epub 2009 Sep 4.
8
Microfluidics: on the slope of enlightenment.微流控技术:处于启蒙阶段
Anal Chem. 2009 Jun 1;81(11):4169-73. doi: 10.1021/ac900638w.
9
Validation of serum biomarkers for detection of early-stage ovarian cancer.用于检测早期卵巢癌的血清生物标志物的验证
Am J Obstet Gynecol. 2009 Jun;200(6):639.e1-5. doi: 10.1016/j.ajog.2008.12.042. Epub 2009 Mar 14.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验